DFE Pharma, a producer of excipients , has expanded its offering for nutraceuticals with the launch of the Nutroféli starch portfolio, comprising of ST100 (native starch), ST200 (partially pregelatinised starch) and ST300 (fully gelatinised starch).
The company says these starches are versatile and naturally sourced, multifunctional excipients, suitable for nutraceutical applications. They can be used for various oral solid dosage forms and reportedly conform to both food and pharma monographs. The portfolio also complies to clean-label requirements.
Nutraceutical products have gained increasing attention in the last few years, even more so since the start of the COVID-19 pandemic, as consumers become more aware about wellbeing, self-care and disease prevention. According to market research from GWI Zeitgeist, the number of US consumers taking vitamin supplements at least occasionally, increased from 36% to 43% since Q1 2020. Furthermore, four in five (79%) US adults take dietary supplements according to the Council for Responsible Nutrition’s 2021 Consumer Survey on dietary supplements from November 2021.
With the launch of the starch portfolio, the company aims to meet nutraceutical manufacturers’ requirements for quality, multifunctional ingredients, while ensuring on-time delivery and security of supply.
Bas van Driel, CEO of DFE Pharma, said: “As a global leader in premium quality ingredient solutions, we support our customers with their formulations to develop and deliver user-friendly dosage designs that appeal to consumers. We understand through more than a century of customized innovation and high quality, multifunctional ingredient solutions, what formulations will best work for our customers. And beyond our wide portfolio for nutraceuticals, we also provide technical expertise and robust application support for global regulations, whatever the requirements are, always following our purpose of moving together to a healthier world”.
